Natalie S Ryan

List of Publications by Year in Descending Order

71 papers	3,505 citations	29 h-index	59 g-index
83 ext. papers	4,787 ext. citations	8.7 avg, IF	4.64 L-index

#	Paper	IF	Citations
71	Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. *Brain*, **2021**, 144, 2964-2970	11.2	6
70	A novel presenilin 1 duplication mutation (Ile168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. *Neurobiology of Aging*, **2021**, 103, 137.e1-137.e5	5.6	0
69	Genetic testing in dementia - utility and clinical strategies. *Nature Reviews Neurology*, **2021**, 17, 23-36	15	4
68	The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease. *Neurobiology of Aging*, **2021**, 97, 10-17	5.6	6
67	Variability in the type and layer distribution of cortical Aβ pathology in familial Alzheimer's disease. *Brain Pathology*, **2021**, e13009	6	1
66	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. *Neuropsychologia*, **2021**, 162, 108028	3.2	2
65	Familial Alzheimer's Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. *Cell Reports*, **2021**, 34, 108615	10.6	18
64	White matter hyperintensity increases are a feature of familial AD and are associated with increased brain atrophy. *Alzheimer's and Dementia*, **2020**, 16, e038925	1.2	
63	Disease duration in autosomal dominant familial Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e039738	1.2	
62	Premature neuronal differentiation in familial Alzheimer's disease human stem cells in vitro and in postmortem brain tissue. *Alzheimer's and Dementia*, **2020**, 16, e039793	1.2	
61	Plasma phospho-tau in familial Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e042921	1.2	
60	Clinical Association of White Matter Hyperintensities Localization in a Mexican Family with Spastic Paraparesis Carrying the PSEN1 A431E Mutation. *Journal of Alzheimer's Disease*, **2020**, 73, 1075-1083	4.3	3
59	Disease duration in autosomal dominant familial Alzheimer disease: A survival analysis. *Neurology: Genetics*, **2020**, 6, e507	3.8	4
58	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. *Molecular Psychiatry*, **2020**,	15.1	36
57	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. *Alzheimer's Research and Therapy*, **2020**, 12, 126	9	4
56	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. *Alzheimer's Research and Therapy*, **2020**, 12, 112	9	7
55	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. *Molecular Psychiatry*, **2020**, 25, 2919-2931	15.1	51

54	CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease. *Neurobiology of Aging*, **2020**, 91, 5-14	5.6	13
53	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. *Brain*, **2019**, 142, 2082-2095	11.2	36
52	Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ-secretase modulators. *EMBO Journal*, **2019**, 38,	13	24
51	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. *Alzheimer's Research and Therapy*, **2019**, 11, 19	9	47
50	Amyloid precursor protein processing in human neurons with an allelic series of the intron 4 deletion mutation and total presenilin-1 knockout. *Brain Communications*, **2019**, 1, fcz024	4.5	8
49	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
48	O3-03-01: THE SEQUENCE AND TIMING OF PRECLINICAL COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE **2019**, 15, P882-P882		1
47	P1-188: MODELLING AMYLOID BETA PROFILES IN IPSC-DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE **2018**, 14, P350-P351		
46	O2-04-04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE **2018**, 14, P623-P624		
45	P1-524: VISUAL SHORT-TERM BINDING DEFICIT IN FAMILIAL ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY **2018**, 14, P532-P533		1
44	P3-461: THE DISTRIBUTION OF CORTICAL Aβ AND MICROGLIAL PATHOLOGY IN FAMILIAL ALZHEIMER'S DISEASE **2018**, 14, P1295-P1295		
43	P3-261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE **2018**, 14, P1174-P1175		
42	Consensus classification of posterior cortical atrophy. *Alzheimer's and Dementia*, **2017**, 13, 870-884	1.2	261
41	Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. *Neurology*, **2017**, 89, 2167-2175	6.5	154
40	Alzheimer's-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβ Interactions. *Cell*, **2017**, 170, 443-456.e14	56.2	127
39	[P4–061]: LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL AND NEUROIMAGING PROGRESSION IN POSTERIOR CORTICAL ATROPHY **2017**, 13, P1382-P1383		
38	Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease. *Brain Research*, **2017**, 1655, 23-32	3.7	21
37	[P1–219]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D **2017**, 13, P327-P327		

36	[P1220]: 3D CEREBRAL ORGANOIDS AS IN VITRO MODELS FOR ALZHEIMER's DISEASE **2017**, 13, P327-P327		
35	[P1025]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2D AND 3D **2017**, 13, P242		
34	[P1180]: DISTINCT A PRODUCTION IN STEM CELL-DERIVED CORTICAL NEURONS FROM PATIENTS WITH FAD MUTATION **2017**, 13, P311-P312		
33	[F4010 4]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE **2017**, 13, P1211		
32	[O4020 4]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY **2017**, 13, P1230-P1231		
31	Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study. *Neurology*, **2016**, 87, 2050-2057	6.5	43
30	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. *Lancet Neurology, The*, **2016**, 15, 1326-1335	24.1	109
29	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. *Annals of Neurology*, **2016**, 79, 929-39	9.4	247
28	O2-03-02: are White Matter Hyperintensities a Core Feature of Alzheimer Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN) **2016**, 12, P226-P226		1
27	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimer Disease **2016**, 12, P231-P231		2
26	F5-02-02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian **2016**, 12, P368-P369		
25	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. *Alzheimer's and Dementia*, **2016**, 12, 862-71	1.2	64
24	Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy. *Brain*, **2015**, 138, 1976-91	11.2	53
23	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 3140-3151	5.6	46
22	Qualitative changes in human secretase underlie familial Alzheimer's disease. *Journal of Experimental Medicine*, **2015**, 212, 2003-13	16.6	104
21	Alzheimer's disease in the 100 years since Alzheimer's death. *Brain*, **2015**, 138, 3816-21	11.2	27
20	Diffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration. *Alzheimer's Research and Therapy*, **2015**, 7, 47	9	83
19	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. *Human Molecular Genetics*, **2015**, 24, 5260-9	5.6	83

18	Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease. *Journal of Alzheimer's Disease*, **2015**, 44, 1069-74	4.3	16
17	Motor features in posterior cortical atrophy and their imaging correlates. *Neurobiology of Aging*, **2014**, 35, 2845-2857	5.6	21
16	IC-P-193: AUTOMATED SEGMENTATION OF THALAMUS FROM MRI: METHOD VALIDATION AND COMPARISON FOR VOLUMETRIC MEASUREMENT IN FAMILIAL ALZHEIMER'S DISEASE **2014**, 10, P107-P108		
15	Imaging endpoints for clinical trials in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2014**, 6, 87	9	40
14	An unbiased longitudinal analysis framework for tracking white matter changes using diffusion tensor imaging with application to Alzheimer's disease. *NeuroImage*, **2013**, 72, 153-63	7.9	86
13	Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer's disease. *Brain*, **2013**, 136, e259	11.2	3
12	The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. *Neurology*, **2013**, 81, 1425-33	6.5	56
11	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. *Brain*, **2013**, 136, 1399-414	11.2	148
10	Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations. *Journal of Alzheimer's Disease*, **2013**, 35, 199-212	4.3	31
9	Global gray matter changes in posterior cortical atrophy: a serial imaging study. *Alzheimer's and Dementia*, **2012**, 8, 502-12	1.2	40
8	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 627.e1-627.e12	5.6	58
7	Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. *PLoS ONE*, **2012**, 7, e43099	3.7	35
6	The importance of group-wise registration in tract based spatial statistics study of neurodegeneration: a simulation study in Alzheimer's disease. *PLoS ONE*, **2012**, 7, e45996	3.7	65
5	Cerebral microbleeds in familial Alzheimer's disease. *Brain*, **2012**, 135, e201; author reply e202	11.2	13
4	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. *Brain*, **2011**, 134, 293-300	11.2	75
3	Correlating familial Alzheimer's disease gene mutations with clinical phenotype. *Biomarkers in Medicine*, **2010**, 4, 99-112	2.3	113
2	Imaging biomarkers in Alzheimer's disease. *Annals of the New York Academy of Sciences*, **2009**, 1180, 20-7	6.5	7
1	Molecular and cellular pathology of monogenic Alzheimer's disease at single cell resolution		4